Market revenue in 2023 | USD 288.1 million |
Market revenue in 2030 | USD 534.7 million |
Growth rate | 9.2% (CAGR from 2023 to 2030) |
Largest segment | Volumetric infusion pumps |
Fastest growing segment | Insulin Infusion Pumps |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Volumetric Infusion Pumps, Syringe Infusion Pumps, Insulin Infusion Pumps, Enteral Infusion Pumps, Ambulatory Infusion Pumps, Patient-Controlled Analgesia Infusion Pumps, Implantable Infusion Pumps, Other Infusion Pumps |
Key market players worldwide | Baxter International Inc, B. Braun, Medtronic PLC, Micrel Medical Devices, Boston Scientific Corp, Fresenius SE & Co KGaA, Roche Holding AG, Tandem Diabetes Care Inc, Terumo Corp, Moog Inc A, IRadimed Corp, CareFusion, Smiths Group PLC, Mindray Medical International |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to intravenous infusion pumps market will help companies and investors design strategic landscapes.
Volumetric infusion pumps was the largest segment with a revenue share of 16.83% in 2023. Horizon Databook has segmented the China intravenous infusion pumps market based on volumetric infusion pumps, syringe infusion pumps, insulin infusion pumps, enteral infusion pumps, ambulatory infusion pumps, patient-controlled analgesia infusion pumps, implantable infusion pumps, other infusion pumps covering the revenue growth of each sub-segment from 2018 to 2030.
China is one of the more favorable emerging markets in the world, mainly because of its large population, low cost of manufacturing, and strong R&D. China’s population is aging, and, like many countries, its major disease burden is chronic illnesses.
According to WHO, approximately 80% of deaths in China are due to chronic illnesses, including cardiovascular disease, stroke, cancer, COPD, and diabetes. This epidemiological transition has aided the growth of the country’s intravenous infusion pumps market.
Behavioral factors such as unhealthy diets, physical inactivity, smoking, and increased stress have boosted the prevalence of chronic diseases. Factors such as technological advancements are playing a major role in growth of the infusion pumps market.
Horizon Databook provides a detailed overview of country-level data and insights on the China intravenous infusion pumps market , including forecasts for subscribers. This country databook contains high-level insights into China intravenous infusion pumps market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account